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Background: Transthyretin (TTR) aggregation is associated with systemic amyloidosis.
Results: Residue replacements on the F and H strands hinder TTR aggregation.
Conclusion: The F and H strands are aggregation-driving segments of TTR. The binding of designed peptides inhibits protein
aggregation.
Significance: We point the way to new therapeutic approaches against TTR aggregation by using peptides to block amyloid
segments.
The tetrameric thyroxine transport protein transthyretin
(TTR) forms amyloid fibrils upon dissociation and monomer
unfolding. The aggregation of transthyretin has been reported
as the cause of the life-threatening transthyretin amyloidosis.
The standard treatment of familial cases of TTR amyloidosis
has been liver transplantation. Although aggregation-prevent-
ing strategies involving ligands are known, understanding the
mechanismofTTRaggregation can lead to additional inhibition
approaches. Several models of TTR amyloid fibrils have been
proposed, but the segments that drive aggregation of the protein
have remained unknown. Here we identify-strands F andH as
necessary for TTR aggregation. Based on the crystal structures
of these segments, we designed two non-natural peptide inhib-
itors that block aggregation. This work provides the first char-
acterization of peptide inhibitors for TTR aggregation, estab-
lishing a novel therapeutic strategy.
Transthyretin (TTR)3 is a 55-kDa protein that aggregates
into amyloid fibrils under pathological conditions. In its native
tetrameric conformation, TTR transports retinol-binding
protein and thyroxine (T4) in the blood and cerebrospinal
fluid (1). T4 binds in a hydrophobic pocket at the center of
the tetramer. Amyloid aggregation of TTR occurs by disso-
ciation of tetrameric TTR into monomers; these partially
unfold into amyloidogenic intermediates and self-associate
into soluble oligomers and amyloid aggregates (2–7). Famil-
ial point mutations are known to destabilize the tetramer,
leading to faster dissociation and consequent amyloid aggre-
gation (8). Compounds that bind to the hydrophobic
T4-binding site are known to stabilize the tetramer and slow
aggregation (9, 10).
The aggregation of TTR causes transthyretin amyloidosis
(ATTR) associated with three conditions traditionally known
as senile systemic amyloidosis, familial amyloidotic polyneu-
ropathy, and familial amyloidotic cardiomyopathy. Senile sys-
temic amyloidosis is a late onset disease in which wild-type
(WT) TTR aggregates, weakening the heart muscle (2, 11).
Senile systemic amyloidosis is usually diagnosed by post-mor-
tem exams of patients over 80 years old. Familial amyloidotic
polyneuropathy and familial amyloidotic cardiomyopathy are
hereditary conditions characterized by extracellular deposition
of TTR amyloid fibrils in the peripheral nerves and heart,
respectively, which leads to system failure (12). Familial amy-
loidotic polyneuropathy is caused by a number of TTR muta-
tions, including L55P and V30M, which we examine here (13).
Themost common familial amyloidotic cardiomyopathymuta-
tion, V122I, is carried by 3.9% of the African-American popu-
lation (14, 15).
Currently, there is no cure for transthyretin amyloidosis, and
the treatment for familial cases of ATTR is liver transplanta-
tion. Tafamidis, a TTR tetramer stabilizer, has been recently
approved in Europe; it delays progression of the disease. Several
other therapeutics are currently in clinical trials, including
other tetramer stabilizers such as diflunisal and RNAi therapies
that cause a decrease in the production ofTTRprotein (16–18).
Additional approaches are needed to prevent ATTR, and here
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we explore the use of peptide inhibitors that block aggregation
of TTR.
Several models of the TTR amyloid spine have been pro-
posed (19–22), but the aggregation-prone segments of the pro-
tein remain uncertain. Based on the studies of crystal structures
of amyloid-driving segments, our group has proposed that
fibrils can form through intermolecular self-association of
one to several fibril-driving segments. Identical segments
from several protein molecules stack into steric zipper struc-
tures, which form the spine of the amyloid fibril through
tightly interdigitated -sheets (23–25). Here we identify two
segments of TTR that drive protein aggregation by self-as-
sociation and formation of steric zipper spines of amyloid
fibrils. Based on the amyloid structure of these two seg-
ments, we designed two peptide inhibitors that halt the pro-
gression of TTR aggregation.
Experimental Procedures
Preparation of Recombinant TTR—Mutants of TTR were
produced using a QuikChange site-directed mutagenesis kit
(Stratagene). Wild-type and mutated TTR genes were cloned
into the pET24() vector (Novagen), and the sequences were
verified by DNA sequencing and/or later x-ray crystallography
of pure proteins (Table 1). For protein expression, exponen-
tially growing Escherichia coli RosettaTM(DE3) pLysS com-
petent cells (Millipore) transformed with each of the plas-
mids were exponentially grown and treated with 1 mM
isopropyl -D-thiogalactoside for 3 h. Wild-type TTR or its
variants were purified by nickel affinity chromatography
using HisTrap columns (GE Healthcare) following the man-
ufacturer’s instructions. Fractions were pooled and sub-
jected to gel filtration chromatography using a HiLoad 16/60
Superdex 75 gel filtration column (GE Healthcare) running
on an ÄKTA FPLC system. TTR-rich fractions were con-
firmed by SDS-PAGE. After checking that the His tag did not
modify TTR aggregation (data not shown), we chose to
retain the tag to facilitate further analysis of TTR aggrega-
tion by His probe blotting.
TTR Aggregation Assay—TTR aggregation assays are de-
scribed elsewhere (26). Briefly, 1 mg/ml TTR sample in 10 mM
sodium acetate (pH 4.3), 100 mM KCl, 10 mM EDTA was incu-
bated at 37 °C for amaximum of 4 days. Variousmeasurements
of TTR aggregation were taken. (i) Protein aggregation was
monitored by measuring absorbance of the sample at 400 nm.
(ii) Protein concentration of the insoluble fraction was calcu-
lated as follows. 100l of sample was spun at 13,000 rpm for 30
min. The pellet was resuspended in the same volume of fresh
buffer and spun again at 13,000 rpm for 30min. The final pellet
was resuspended in 6 M guanidine chloride, and absorbance at
295 nm was measured. Protein concentration of the insoluble
fraction was calculated from absorbance data at 295 nm. (iii)
TTR aggregation was visualized by transmission electron
microscopy of the sample and/or immunodot blot of the insol-
uble fraction.
Aggregation assays were performed in both the presence and
absence of aggregation inhibitors when appropriate at a ratio of
1:10 (TTR monomer:inhibitor) unless labeled otherwise. Tur-
bidity of the sample (absorbance at 400 nm) and protein con-
centration of the insoluble fraction were measured at time 0,
day 1, day 2, and day 4. Values for day 4 are presented in the
figures unless labeled otherwise.
Immunodot Blot—The aggregation of TTR was followed by
dot blot analysis as described (27) using the SuperSignalWest
HisProbeTM kit following the manufacturer’s instructions
(Thermo Scientific). The insoluble fraction of the samples after
4 days of incubationwas dotted onto nitrocellulosemembranes
(0.2 m; Bio-Rad). A dilution ratio of 1:10,000 was used for the
HisProbe antibody.
Fibril Formation of TTRPeptides—Peptideswere dissolved in
PBS buffer (pH 7.4) at a concentration that depended on the
solubility of the peptide: 12LMVKVL17 at 14 mM, 25AINVAV30
at 17 mM, 26NVAVHV32 at 16 mM, 28VAVHVF33 at 15 mM,
47GKTSES52 at 16mM, 65VEGIYK70 at 14mM, 68IYKVEI73 at 13
mM, 80KALGIS85 at 17mM, 91AEVVFT96 at 0.5mM, 91APVVFT96 at
15.8 mM, 91AEVPFT96 at 15.8 mM, 105YTIAAL110 at 15 mM,
106TIAALLS112 4.6 mM, and 119TAVVTN124 at 17 mM. Follow-
ing dissolution, samples were filtered through a 0.2-m filter
and incubated at 37 °C with no shaking for 2 weeks.
Transmission Electron Microscopy (TEM)—TEM was per-
formed to visualize the fibril formation of TTR proteins and
peptides. 5 l of the sample was spotted onto freshly glow-
discharged, carbon-coated EM grids (Ted Pella, Redding,
CA). After 3 min of incubation, grids were rinsed three times
with 5 l of distilled water and then stained with 2% uranyl
acetate for 2 min. Grids were examined with a T12 Quick
CryoEM and CryoET (FEI) transmission electron micro-
scope at an accelerating voltage of 120 kV. Digital images
were recorded using a Gatan 2,048  2,048 charge-coupled
device camera.
Crystallization and Structure Determination—Crystalliza-
tion conditions, data collection, and refinement statistics of
crystal structures are detailed in Table 1. X-ray diffraction data
were collected at the Advanced Photon Source beamline
24-ID-C (for full-length proteins) or 24-ID-E (for peptides).
Molecular replacement was performed with the program
Phaser (28) using as search models an idealized polyalanine
-strand and chain A of the mutant T119M (Protein Data
Bank code 1F86) for peptide and TTR variant data sets,
respectively. Crystallographic refinement was performed
using PHENIX (29), REFMAC (30), and BUSTER (31).
Model building was performed with Coot (32) and illustrated
with PyMOL (33).
Sequence and Structure Analysis—To predict amyloidoge-
nicity of TTR segments, the TTR sequence was submitted to
ZipperDB, the Rosetta-based method that profiles the steric
zipper spine, the main structural feature of amyloid fibrils (34,
35). Additionally, solvent-accessible surface area per residue
of TTR was calculated to examine the accessibility of the
different protein segments for self-association. Solvent-ac-
cessible surface area calculations were performed by
Areaimol (36) using the structure of WT TTR (Protein Data
Bank code 4TLT) in three different conformations: tetramer
with 222 symmetry, dimer (the crystallographic asymmetric
unit), and monomer (by removing one chain of the dimer).
These conformations are based on the dissociation pathway
described elsewhere (4).
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Design of Aggregation Inhibitors—We predicted the interac-
tion of the peptidesAEVVFTandTAVVTNwith their identical
segments at the surface of the monomer or at the tip of a grow-
ing steric zipper of TTR based on our finding that the two TTR
segments form fibrils in solution by self-aggregation. To vali-
date the prediction, computational docking was carried out
using the Rosetta software as described previously (35) using
chain A of WT TTR as a template (Protein Data Bank code
4TLT). The optimization of the aggregation inhibitors required
the addition of an N-methyl group and tetra-arginine tag. The
use of the non-naturalN-methyl groups to protect aggregation
inhibitors from proteolysis has been successful in other aggre-
gation inhibitors (37). The addition of a polyarginine tag con-
fers higher solubility and we presume also hinders self-aggre-
gation of the inhibitors. The position of the N-methyl group
was designed based on our docking model and experimentally
checked by aggregation assays.
Differential Scanning Calorimetry—Data were taken with a
DSC-II differential scanning calorimeter (Calorimetry Sciences
Corp., Lindon, UT). Themidpoint temperatures of the thermal
unfolding transition (Tm) of wild type and mutants were deter-
mined. Thermal denaturation of TTR was irreversible under
our conditions (1, 38), and absolute thermodynamic parame-
ters were not determined. Previously, researchers found that
WT TTR unfolds at 101.7 °C under 2 atm of nitrogen (39). The
experiments were performed in 3.5 M guanidinium hydrochlo-
ride to depressmelting below 100 °C; this guanidinium concen-
tration also solubilized thyroxine. Protein samples were thawed
on ice and filtered, and the concentration was measured by
UV-visible absorption. Protein samples were diluted to 1
mg/ml in 3.5 M guanidinium chloride, 100 mM sodium acetate
(pH 4.3), 100mMpotassium chloride, 1mMEDTA. A volume of
700 l of each protein sample was prepared in a 1.5-ml micro-
centrifuge tube and degassed for 5 min under vacuum while
stirring. The reference cell contained only buffer components.
Samples were scanned from 25 to 95 °C at a rate of 1 °C/min.
The buffer was subtracted, and the baseline was corrected with
the linear polynomial function in CPCalc Analysis software. In
an additional experiment, T4 and aggregation inhibitors were
added to WT TTR to determine whether they affect the ther-
modynamic stability. T4 and the aggregation inhibitors were
added in 5-fold excess relative to protein concentration to both
the reference and sample chambers.
Non-denaturingElectrophoresis—Monomeric variantMTTRat
0.5mg/ml (40)was incubatedwith increasing concentrations of
both TTR inhibitors R4PAm and R4PTm (0–5-fold molar
excess) and subjected to blue native electrophoresis using
NativePAGETM Bis-Tris precast gels (4–16% Bis-Tris, 1 mm;
Life Technologies) following the manufacturer’s instructions.
NativeMarkTM unstained standards were used for size estima-
tion of proteins.
Binding Constant Calculations—The soluble unbound frac-
tion of inhibitors after incubation with the monomeric variant
MTTR (40) was quantified by HPLC-MS. Samples were made
as follows. Soluble TTR at a fixed concentration of 0.5 mg/ml
was incubated at 37 °C for 18 h in 10 mM sodium acetate (pH
7.4), 100 mM KCl, 10 mM EDTA with increasing quantities of
combined R4PAm and R4PTm. The aggregated fraction was
removed by 0.22-m filtration. The protein fraction containing
soluble TTR and inhibitor-bound complexeswas then removed
by acid precipitation with 1% acetic acid and consecutive ultra-
centrifugation at 90,000 rpm for 30 min. Neither 0.22-m fil-
tration nor acid precipitation affected the concentration of the
unbound soluble fraction of the peptide inhibitors (data not
shown). The unbound soluble fraction of inhibitors was sub-
jected to size exclusion HPLC followed by mass spectrometry.
The instrument used was the Agilent 6460 Triple Quadrupole
LC/MS System (Agilent Technologies, Santa Clara, CA) with
a TSK gel column (2.0  150 mm, 4 m, 125 Å; Michrom
Bioresources, Inc., Auburn, CA). Flow rate was 0.2 ml/min,
and the elution buffer was 75% acetonitrile in water contain-
ing 0.1% formic acid. Known concentrations of peptide
inhibitors were subjected to the same treatment to create a
standard curve. The analysis of the results was performed
using GraphPad Prism 6.
Analytical Size Exclusion Chromatography—To analyze the
tetrameric and monomeric populations of TTR, the variant
M13R/L17R/T119M (MLT) was generated. This variant forms
tetramer and monomers in solution that were examined as fol-
lows. A 5-fold molar excess of TTR inhibitors was added to 1
mg/ml soluble MLT and analyzed before and after incubation
in 10mM sodium acetate (pH 4.3), 100mMKCl, 10mMEDTAat
37 °C for 18 h. Samples were analyzed by analytical size exclu-
sion with a Superdex 75 16/300 GL column following the man-
ufacturer’s instructions (GE Healthcare) running on an ÄKTA
FPLC system in 10mM sodiumacetate (pH7.4), 100mMKCl, 10
mM EDTA.
Results
Identifying the Amyloid-driving Segments of TTR—Our first
step toward identifying the amyloid spine-forming segments of
TTR was to test candidate segments identified by computa-
tional predictions for their ability to aggregate. We used the
structure-based, computational method ZipperDB to predict
6-amino acid segments of TTR likely to form amyloid fibrils
(34, 35). Of the 14 segments thatmet the threshold of ZipperDB
(Fig. 1A, red bars), we experimentally tested 12 for their pro-
pensity to form fibrils in isolation. Eight of the 12 segments
formed amyloid-like aggregates having fibrillar morphology (as
viewed by electron microscopy; Fig. 1B) and cross- x-ray dif-
fraction characteristic of amyloid (Fig. 1C) (41, 42). The seg-
ments that formed fibrils reside in the -helix and -strands A,
B, F, G, and H of the native structure of TTR. Based on these
results, we hypothesized that any of these eight segments could
potentially drive TTR aggregation.
To pinpoint which of the eight segments drives aggregation
within full-length TTR, we created individual proline substitu-
tionswithin each segment.We chose the substitution to proline
because it is known to inhibit fibril formation (43, 44). None of
the proline variants fully halted TTR aggregation (Fig. 2, A and
B), but substitutions S85P, E92P, and V94P and the S85P/E92P
double substitution significantly decreased protein aggregation
and altered aggregate morphology (Fig. 2A). In the isolated
segment 91AEVVFT96, proline replacements in positions 92
and 94 completely prevented fibrillization (Fig. 2C). These
data suggest that the 91AEVVFT96 segment and the N-termi-
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nally adjacent region of full-length TTR are important for fibril
formation.
To better understand how 91AEVVFT96 self-associates to
form fibrils, we determined the structure of the fibril-like crys-
tals of 91AEVVFT96. We found that it forms a Class-7 steric
zipper (Ref. 25 and Fig. 2D) in which the -strands stack into
antiparallel -sheets with identical side chains on both faces.
This structure shows how 91AEVVFT96 may self-associate in
driving TTR aggregation.
Next, we considered the possibility that TTR contains more
than one aggregation-driving segment. Experiments of others
show that the fibril core of TTR contains most of the protein,
suggesting thatmore than one segment participates in the fibril
core (19, 45). Because the monomeric state is more amyloido-
genic than the tetrameric state (4), we reasoned that fibril-driv-
ing segments are buried in the tetramer but exposed in the
monomer. In this situation, the segments would be exposed to
bind to identical segments from other monomers to form a
fibril. We analyzed the solvent-accessible surface area of TTR
and found that -strand F is indeed more exposed in the TTR
monomer than in the dimer or tetramer (Fig. 3A). A second
regionwas alsomore exposed in themonomer:-strandH.We
therefore tested whether -strand H might also be a driver of
TTR aggregation.
We found that strand H also contributes to TTR amyloid
aggregation but not by applying the method of proline substi-
tution that was effective with strand F. Proline substitutions in
strandHdid not hinderTTR aggregation (Fig. 2). Therefore, we
decided to disrupt the capacity for a steric zipper by strandHby
substituting residues Thr119 and Val121 with the bulky residues
tyrosine and tryptophan. The size of these side chains is
expected to prevent formation of tightly packed steric zippers
formed from amino acids with short side chains such as Thr119
andVal121. Aggregation assays of TTR variants showed that the
mutants T119W, T119Y, V121W, and V121Y did not produce
aggregates after 4 days of incubation (Fig. 3B). For additional
evidence, we synthesized and analyzed 6-residue peptides con-
taining the same substitutions, and they did not form aggre-
gates or fibrils in isolation (Fig. 3C). These experiments suggest
that strandH plays a role during TTR aggregation by acting as a
fibril-forming segment.
Next, we performed structural analysis of the isolated strand
H segment to test whether it forms a steric zipper structure.We
found that 119TAVVTN124 forms aClass-2 steric zipper (Ref. 25
and Fig. 3D) in which the -strands stack into parallel -sheets
with one sheet face packing against another sheet back. Taken
together, these experiments suggest that the 119TAVVTN124
segment is important for fibril formation.
Validation of the Role of Strands F and H in Aggregation by
the Design of Amyloid Inhibitors—To confirm that strands F
and H drive protein aggregation, we tested aggregation inhibi-
tion by short peptides that we designed to bind to strands F and
H, thereby shielding them fromaggregation.Wedesigned amy-
loid inhibitors against -strands F and H using prior strategies
that have been successful at blocking aggregation of other pro-
teins (46, 47). The design was supported by protein-protein
docking (Fig. 4). To create aggregation inhibitors capable of
binding the target sequence without self-associating, we mod-
ified the sequences 91AEVVFT96 and 119TAVVTN124 by adding
non-natural amino acids and a charged tag. We used the dock-
ing model to predict the most suitable positions for N-methy-
lated residues. The model predicted that even positions (Glu92,
FIGURE 1. Identifying amyloidogenic segments in TTR. A, propensities of steric zipper formation of each 6-residue segment within the TTR sequence.
Computationally predicted segments with steric zipper propensities are represented with red bars. The schematic of the secondary structure of native TTR is
shown on top of the sequence. Black arrowsmark residueswhere proline replacement did not hinder TTR aggregation. Blue arrowsmark proline replacements
that hinderedTTR aggregation. Thegreenarrowmarks themutation T119M,whichprotects TTR against fibril formation (58). Thegreen andblue boxeshighlight
the segment sequences critical for TTR aggregation that we described in this study. B, TEMmicrographs of the fibrils formed after 7 days of incubation (scale
bar, 500 nm). C, amyloid x-ray cross- diffraction pattern of the samples containing fibrils shown in B. The arrowheads point to the meridional reflection at
4.7–4.8-Å spacings (parallel to the fibril axis; black arrowheads) and equatorial reflections at10-Å spacings (white arrowheads). Notice that all eight of the
examined segments predicted to form amyloid fibrils do in fact form amyloid fibrils.
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Val94, and Thr96 from 91AEVVFT96 and Ala120, Val122, and
Asn124 from 119TAVVTN124) were more favorable than odd
positions (Fig. 4C). This prediction was later supported by
experiments.
Fifteen different peptides were tested as potential inhibitors
of aggregation (Fig. 5). The peptide sequences are listed in Fig.
5A. We began by testing the 6-residue F- and H-strand pep-
tides, AEVVFT andTAVVTN,with sequentialmodifications of
N-methylated amino acids (Fig. 5B). The experimental obser-
vation that the aggregation inhibitorswithN-methyl residues at
even positions were more effective than those with N-methy-
lated odd positions agreeswith our dockingmodel (Figs. 4C and
5B). We next added an N-terminal tag of four arginine residues
to further improve the inhibitors by increasing their solubility
and preventing self-aggregation. The addition of the N-termi-
nal residues significantly increased the inhibition (Fig. 5B). The
position of the tag was also tested at both termini, andwe found
that the N-terminally tagged peptides were better inhibitors
(Fig. 5C).
We assessed the specificity of the inhibitors in two ways.
First, we tested a scrambled control peptide with the polyargi-
nine tag intact (Fig. 5B). Charged tags might form salt bridges
with several of the loops in TTR that are rich in acidic residues
(48). The control peptide did not disrupt protein aggregation,
confirming that the aggregation inhibition is sequence-specific
and not reliant on the arginine tag (Fig. 5B). Then we tested the
combination of F and H inhibitors. The peptides R4PAm and
R4PTm showed a synergistic effect, suggesting two different
binding sites (Fig. 5B), in a dose-dependent manner (Fig. 5D).
The combination was also effective at blocking aggregation of
the familialmutants V30Mand L55P at physiological TTR con-
centration (Fig. 5E). Based on this initial screening, the two
peptides R4PAm and R4PTm in combination were selected for
further study.
To further characterize the mechanism of action of the
inhibitor pair, we examined their effect on different assembly
states of TTR. First, we examined tetramer stability by differ-
ential scanning calorimetry (Fig. 6A). We found that the inhib-
FIGURE 2.-Strand F as an aggregation-driving segment in TTR suitable for aggregation inhibitor design. TTR aggregation of the protein variants that
showed significant delay (A) and those that did not decrease protein aggregation (B) is shown. Those TTR proline variants that are not shown herewere found
to be insoluble. Histograms show percentage of TTR aggregation using WT TTR to normalize to 100%. The aggregation was measured by absorbance of the
samples at 400 nm after 4 days of incubation at 37 °C and pH 4.3 with no shaking. The bottom panel shows a His probe dot blot of the insoluble fraction
corresponding to the sample above after solubilization with guanidinium hydrochloride. On the right are TEMmicrographs of protein aggregates (scale bar,
100 nm) after 7 days of incubation. Notice that the proline substitutions within or next to -strand F hindered TTR aggregation. Several of the other proline
substitutions enhanced aggregation; these, like ATTR familial mutations, may alter native structure and/or protein stability (8). Error bars represent S.D., and **
symbolizes a p value0.003 (n 3). C, TEMmicrographs of peptides in isolation after 7 days of incubation in PBSwith no shaking (scale bar, 500 nm).D, crystal
structure of the segment 91AEVVFT96 from -strand F forming a Class-7 steric zipper. One sheet is shown as blue; the other is shown as gray. On the left
is a lateral view of the fibril with the fibril axis shown by the narrow black arrow. On the right is the view down the fibril axis showing two -sheets in
projection. Water molecules are shown as aquamarine spheres. Spheres represent the van der Waals radii of the side chain atoms of the tightly packed
fibril core.
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itors did not affectWTTTR stability or compete with T4 for its
binding site (Fig. 6A). These results confirm that the mecha-
nism for inhibiting aggregation is different from tetramer sta-
bilization (9, 10, 49). Additionally, we examined the effect on
oligomer formation of an engineered monomeric variant of
TTR, MTTR (40). MTTR has two methionine substitutions at
residues Phe87 and Leu110, which prevent dimer and tetramer
formation, leading to rapid aggregation at acidic pH. Incuba-
FIGURE 3. -Strand H as a second aggregation-driving segment suitable as a target for aggregation inhibitor design. A, residue solvent-accessible
surface area (ASA; Å2) of TTR was calculated by Areaimol using the structure of WT TTR in three different conformations: tetramer (blue), dimer (black), and
monomer (green). Notice that the strands F and H are indeed more exposed when TTR is in a monomeric form. 5.7% of the surface of the amyloidogenic
segment 91AEVVFT96 is solvent-exposed in the tetramer, 5.7% is exposed in the dimer, and 32.1% is exposed in themonomer. Additionally, the amyloidogenic
segment 119TAVVTN124 from strand H is 27.4% solvent-exposed in the tetramer, 43.4% solvent-exposed in the dimer, and 55.3% solvent-exposed in the
monomer. B, TTR aggregation of variants with substitutions on strand H. The histogram at the top shows the percentage of TTR aggregation after 4 days of
incubation measured by absorbance at 400 nm with WT aggregation normalized to 100%. Below, a His probe dot blot shows the insoluble fraction of the
samples after 4 days of incubation and solubilizationwith guanidiniumhydrochloride. Bottompanels, TEM images from the samples after 7 days of incubation.
These show that the substitutions of residues Thr119 and Val121 did indeed hinder protein aggregation. Error bars represent S.D., and ** symbolizes a p value
0.003 (n 3). C, TEM micrographs of peptides in isolation after 7 days of incubation in PBS with no shaking (scale bar, 500 nm). D, crystal structure of the
segment 119TAVVTN124 from-strandH forming a Class-2 steric zipper. One sheet of the zipper is gray; the other is green. On the left is a lateral view of the fibril
with the fibril axis indicated by the narrow black arrow. On the right is the view down the fibril axis showing two -sheets in projection. Spheres represent the
van der Waals radii of the side chain atoms of the tightly packed fibril core.
FIGURE4.Designof sequence-specificpeptide inhibitorsofTTRaggregation.A, computational dockingmodelof thepeptidesAEVVFTandTAVVTNbound
to strands F (blue) and H (green), respectively, of the TTR monomer. Peptides are shown with translucent spheres representing van der Waals radii; the TTR
monomer is shown as ribbons with side chains of strands F and H as sticks. B, lateral, close-up view of the F and H strands in the docking model showing the
designed pattern of hydrogen bonding (dashed lines) between the peptides (sticks) and the TTR -strands (ribbon with sticks). C, docking models of N-meth-
ylated peptides predict which will bind TTR (same view as B). N-Methylations were added to increase peptide solubility, reduce aggregation, and reduce
sensitivity.Colored spheres represent the van derWaals radii of theN-methyl groups (Nme) in favorable positions; yellow starshighlight clashes of theN-methyl
modifications with the TTR monomer.
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tion of MTTR with the inhibitor pair reduced oligomer forma-
tion as monitored by non-denaturing gel electrophoresis (Fig.
6B). The analysis of the binding of the TTR inhibitors toMTTR
species showed an apparent binding constant of 17.9 6.1 and
19.3  6.7 M for R4PAm and R4PTm, respectively (Fig. 6C).
This experiment did not exclude the binding of the inhibitors to
aggregated species. The measured affinity is therefore a com-
bined affinity for all species in solution, and the mono-
mer-specific affinity might be weaker than calculated.
We next found that the presence of inhibitors leads to an
equilibrium shift toward the tetramer population.We first gen-
erated the TTR variant MLT, which exhibits monomers and
tetramers in solution, andwe analyzed both populations by size
exclusion chromatography (Fig. 6D). The results show that the
addition of inhibitors promotes an immediate increase in
tetramer concentration when compared with the absence of
inhibitors. Additionally, themonomeric concentration remains
unchanged after incubation for 18 h in the presence of the
inhibitors, whereas their absence results in monomer loss and
aggregation. Taken together, these results suggest amechanism
of action that does not stabilize the monomer population and
differs from the tetramer stabilization.
In summary, our results indicate that strands F and H play a
causative role in TTR aggregation. We used this hypothesis to
design inhibitors of their self-aggregation to stop amyloid for-
mation of wild-type TTR and familial mutant variants.
Discussion
TTR aggregation is linked to ATTR, a condition that is not
yet curable (50). Although new strategies are being evaluated
(16–18), the development of combinatory systems that address
various molecular processes driving TTR aggregation is desir-
able to maximize treatment options. Here we propose a novel
mechanism of aggregation inhibition that consists of targeting
FIGURE 5.Designed peptides are sequence-specific inhibitors of TTR aggregation. A, list of inhibiting peptides tested as TTR aggregation inhibitors. B–E,
evaluation of the peptide inhibitors. The graphs show the percentage of TTR aggregation after 4 days of incubation in the presence or absence of peptide
inhibitor measured by absorbance at 400 nm; WT inhibition-free aggregation was normalized to 100%. The initial concentration of soluble TTR was 1 (B–D)
or 0.2 mg/ml, which corresponds to the concentration of TTR in plasma (E). The molar excess of peptide inhibitor over target (TTR monomer) is 3-fold
unless labeled otherwise. In C and D, a His probe dot blot shows the insoluble fraction of the samples after 4 days of incubation and solubilization with
guanidiniumhydrochloride. B, initial screening of inhibitors showing that threemodifications significantly improved the effectiveness: (i) increasing the
length of the matched sequence of the peptide and the target, (ii) addition of a charged tag, and (iii) addition of an N-methyl group in positions
predicted to be favorable by the docking model (Fig. 4C). The two best inhibitors of TTR aggregation were R4PAm and R4PTm. C, the peptide inhibitors
are more effective with the charged tag at the N terminus than at the C terminus. D, dose-dependent effectiveness of the peptides R4PAm and R4PTm
in combination. Maximal inhibition of TTR aggregation is reached when the target to peptide molar ratio is 1:3. E, aggregation assay of the familial
mutants V30M and L55P in the presence of R4PAm and R4PTm in combination using a physiological concentration of protein (3.6 M). Error bars
represent S.D. (n  3), and ** symbolizes a p value 0.003.
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segments of TTR that are exposed only when the TTR tetramer
dissociates and drive protein aggregation.
Others have shown that a necessary step in the conversion of
TTR to amyloid fibrils is its dissociation to a monomer (2–7),
but the specific segments that cause the aggregation of mono-
mers had not previously been identified. We performed exper-
iments to identify adhesive segments in TTR that participate in
fibril formation. Our procedure was first to identify possible
amyloid-forming segments by ZipperDB three-dimensional
profiling. In this procedure, the TTR sequence is computation-
ally threaded through a “profile” derived from the structure of a
known amyloid fibril (34, 35). This procedure identified 14
steric zipper-forming 6-residue-long segments, eight of which
indeed formed fibrils in solution (Fig. 1). Also our computations
with ZipperDB show that TTR familial mutations do not
increase the propensity of fibril formation (data not shown).
These results support the hypothesis that familial point muta-
tions destabilize the quaternary structure rather than creating
new amyloidogenic segments (8).With systematicmutagenesis
of the eight fibril-forming segments and computational predic-
tion of exposed strands in the monomer, we were able to trace
the cause of TTR fibril formation to the sequence segments that
form the F and H -strands of the native structure.
Mutational analysis of amyloid proteins for identification of
aggregation-driving segments has been reported by our group
and others to be effective (43, 51, 52). These data led us to
strands F and H in the case of TTR (Figs. 2 and 3). However,
mutation to proline, tryptophan, or tyrosine does not necessar-
ily imply prevention from aggregation. As additional evidence,
we tested fibrillization of the segments 91AEVVFT96 and
119TAVVTN124 in isolation as well as their mutated versions to
find that the substitution of residue 85, 92, 94, 119, or 121 did
hinder self-association and fibril formation (Figs. 2 and 3). In
addition, to further prove that -strands F and H can partici-
pate in amyloid core formation of TTR fibrils, we determined
the crystal structure of the steric zippers formed by the seg-
ments in isolation by x-ray crystallography (23–25, 53). The
crystal structure of 91AEVVFT96 revealed a Class-7 steric zip-
per with antiparallel -strands and antiparallel sheets (Ref. 25
and Fig. 2D). The side chain organization explains why the res-
idue replacements E92P and V94P hinder TTR aggregation
because the proline substitution would decrease the shape
complementarity between sheets in the steric zipper structure.
Moreover, the crystal structure of 119TAVVTN124 is a Class-2
steric zipper, face-to-back arrangement with parallel -strands
and parallel sheets (Ref. 25 and Fig. 3D). The side chain organi-
zation in this peptide also explains why the residue replace-
ments T119W,T119Y, V121W, andV121Y impedeTTR aggre-
gation. Because residues Thr119 and Val121 are pointing to the
hydrophobic T4-binding site, we cannot dismiss the possibility
that the tryptophan or tyrosine could strengthen the hydropho-
bic contacts to increase the stability of the protein and delay
aggregation. However, the involvement of these segments in
the formation of TTR fibrils was supported by two pieces of
evidence. First, peptides with Tyr/Trp substitutions did not
form fibrils in isolation (Figs. 2C and 3C). Second, the aggrega-
FIGURE 6.Analysis of themechanism of action of the TTR inhibitors. A, midpoint temperatures of the thermal unfolding transition (Tm) of wild-type TTR at
different conditions were determined by differential scanning calorimetry. Relative stability is compared in the presence and absence of a 5:1molar ratio of T4
and/or the combinationof R4PAmandR4PTmtoTTRmonomer. The TTR concentrationwas 1mg/ml. Notice that the additionof thenatural ligandT4 increased
the protein thermostability by 10.8 °C. The addition of the peptide inhibitors increased it only by 1.3 °C in the absence of T4 and by 0.9 °C when the ligandwas
present. B, inhibition of oligomer formation of MTTR after incubation with R4PTm and R4PAm. A fixed amount of MTTR (0.5 mg/ml) was incubated in the
presence of increasing concentrations of TTR inhibitors (0–5-fold excess) and subjected to non-denaturing electrophoresis. The sizes of His-tagged TTR
monomer (14 kDa) and tetramer (56 kDa) are shown next to the gel. R4PTm and R4PAm inhibited MTTR oligomer formation in a dose-dependent manner. C,
fraction of the inhibitors R4PAm (solid line, squares) and R4PTm (dashed line, circles) bound to MTTR. The soluble fraction of the samples was collected after
ultracentrifugation followed by acid precipitation of soluble MTTR and inhibitor-bound complexes. The unbound fraction of inhibitors was analyzed by
HPLC-MS. One-site specific binding analysis was performed using GraphPad Prism 6 to calculate binding parameters KD as apparent binding affinity and Bmax
asmaximumbound fraction.D, analysis of tetrameric andmonomeric populations ofMLT after incubationwith TTR inhibitors. Size exclusion chromatography
of MLT reveals that the presence of TTR inhibitors does not drive the protein equilibrium to populate the monomeric species. In contrast, an increase of
tetrameric species was found after incubationwith inhibitors (Inh). TTR aggregation (TTR agg.) wasmeasured by absorbance at 400 nmwith the initial protein
amount normalized to 100%.mAU, milli-absorbance units; N.A., not applicable.
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tion inhibitors targeting these segments hindered TTR aggre-
gation (Figs. 5 and 6). We do not dismiss the contribution of
other aggregation-prone segments to the amyloid core. Strands
F and H that we propose here might be segments most suscep-
tible to structural changes in promoting aggregation.
Combining mutational and structural studies of TTR vari-
ants and isolated peptides, we uncovered the involvement of the
strands F and H in TTR aggregation (Figs. 1–3). This finding is
consistent withNMR relaxation dispersion studies that showed
that, at physiological pH, monomeric TTR undergoes confor-
mational fluctuations of the H and F strands that are propa-
gated along the entire sheet (54). Kelly and co-workers (48, 54)
have also analyzed TTR by NMR studies and x-ray crystallog-
raphy in neutral and acidic environments to assess structural
changes. These studies have confirmed that the EF-loop under-
goes large conformational changes when the pH is changed
from neutral to an acidic environment. We speculate that the
S85P substitution, near strand F, constrains this flexibility to
prevent aggregation. Substitutions in strand F, E92P and V94P,
most likely hinder self-recognition and further aggregation.
Kelly and co-workers (40) have engineered a monomeric vari-
ant of TTR that is non-amyloidogenic unless partially dena-
tured. The monomeric variant aggregates much faster than the
wild-type tetramer at pH 4.4 (minutes versus hours, respec-
tively). They also determined the structure of this variant and
showed that most of the deviations from the structure of WT
TTR are observed on the interfaces between the subunits,
involving strands F and H, which supports our findings. We
reasoned that if strands F and H are important for the self-
association of TTR then one could stop protein aggregation by
blocking the two segments.
To validate our identification of the fibril-forming segments,
we designed analog peptides that interact with the F and H
strands. These inhibitors slowed fibril formation, supporting
our identification of the fibril-forming segments (Figs. 5 and 6).
Eisenberg and co-workers (46, 47) have previously used struc-
ture-based design of peptides or compounds to disrupt fibril
development and/or growth. For the design ofTTR aggregation
inhibitors, N-methyl residues were incorporated into the pep-
tide sequence to increase effectiveness (Figs. 4 and 5B). This is
advantageous because non-natural amino acids can increase
peptide stability by reducing proteolytic degradation (37, 55).
This initial screening resulted in two optimized TTR peptide
inhibitors, both 16 residues long, with separate binding sites
that differ from the hydrophobic pocket (Figs. 5B and 6A).
The inhibition of TTR aggregation by peptide inhibitors as a
prospective therapeutic strategy needs further optimization to
improve affinity. Although similar to some amyloid inhibitors
(56, 57), the apparent affinity of the monomeric variant MTTR
(40) to the inhibitors is low compared with those found for
tetramer stabilizers (for instance, see Refs. 9 and 10). However,
the binding of the inhibitors to TTR after tetramer dissociation
might differ from their binding to MTTR.
The inhibition of TTR aggregation by blocking strands F and
H indicates their importance for protein aggregation. Our data
suggest that the aggregation of TTR requires tetramer dissoci-
ation into monomeric species as suggested elsewhere (2–6).
Several other studies propose that TTR aggregation occurs by
dimer arrangement (19–21).However, strands F andHare bur-
ied in the dimer interface (Ref. 4 and Fig. 3A), impeding self-
association. Therefore, the inhibition of TTR aggregation by
interaction of peptide inhibitors with the F and H strands
requires dimer dissociation and segment exposure.
Based on our data, we propose a pathway for peptide-based
inhibition of TTR aggregation (Fig. 7). Upon tetramer dissoci-
ation, the binding of the peptide inhibitors to their identical seg-
ments hinders self-recognition and aggregation. The inhibitor-
bound TTR complex is more stable than the monomer but less
stable than the tetramer (Fig. 6D), thereby favoring tetramer reas-
sembly. Additionally, although the inhibitors were designed to
interactwith theFandHstrands afterdissociationof the tetramer,
theymay act at the amyloid level by capping the emerging fibrils to
hinder further growth (46). In either case, the steric zipper-like
interaction of the peptide inhibitors with the F and H strands
would block self-association and protein aggregation.
In summary, we have shown that strands F andH are actively
involved in TTR aggregation and uncovered a new strategy for
the inhibition of TTR aggregation by small non-natural pep-
tides. Their mechanism of action allows combinatory treat-
ment with tetramer-stabilizing compounds, which might be an
effective therapeutic approach. The two inhibiting peptides
may serve as leads for the development of drugs against TTR
systemic diseases.
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FIGURE 7.Model of peptide-based inhibition of TTR aggregation. The low
free energy of TTR amyloid fibrils drives aggregation with TTR dissociation
providing a kinetic barrier (4). The inhibitors do not affect stability of the TTR
tetramer but bind to intermediate species, hindering unfolding and aggrega-
tion.Althoughtheinhibitor-boundcomplexismorestablethanthefreemono-
mer, it is less stable than the tetramer, thereby favoring tetramer reassembly.
Note that in this scheme the hydrophobic pocket of the tetramer remains
accessible for complementary treatment with a stabilizer compound such as
tafamidis or diflunisal (10, 49).
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